Interpace Diagnostics Group Inc is a United States-based integrated commercial and bioinformatics company. It is engaged in developing and commercializing molecular diagnostic tests, leveraging the technology and personalized medicine for patient diagnosis and management. The company has four commercialized molecular tests, PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts, ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and, ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay, and RespriDX for assessing metastatic versus primary lung cancer tumors. The company's customers consist of physicians, hospitals, and clinics.
| Website: | www.interpacediagnostics.com |
| Email: | jgreen@edisongroup.com |
| Main Phone: | +1 855 776-6419 |
| Address: | 300 Interpace Parkway |
| Address 2: | Building C |
| State: | NJ |
| City / Town: | Parsippany |
| Country: | USA |
| Postal Code: | 07054 |
| Exchange: | NSC |
| CEO: | Jack E. Stover |
| Employees: | 75 |
| NAICS: | Testing Laboratories(541380) |
Gathering Data... Please wait Interpace Diagnostics Group Inc is a United States-based integrated commercial and bioinformatics company. It is engaged in developing and commercializing molecular diagnostic tests, leveraging the technology and personalized medicine for patient diagnosis and management. The company has four commercialized molecular tests, PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts, ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and, ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay, and RespriDX for assessing metastatic versus primary lung cancer tumors. The company's customers consist of physicians, hospitals, and clinics.
| Website: | www.interpacediagnostics.com |
| Email: | jgreen@edisongroup.com |
| Main Phone: | +1 855 776-6419 |
| Address: | 300 Interpace Parkway |
| Address 2: | Building C |
| State: | NJ |
| City / Town: | Parsippany |
| Country: | USA |
| Postal Code: | 07054 |
| Exchange: | NSC |
| CEO: | Jack E. Stover |
| Employees: | 75 |
| NAICS: | Testing Laboratories(541380) |
| Last Price 0.93 | Change $ -0.0042 | Change % -0.45 | Tick N/A |
| Bid 0.93 | Bid Size 400.00 | Ask 0.95 | Ask Size 12,600.00 |
| Open 0.95 | High 0.95 | Low 0.92 | Prev Close 0.93 |
| Last Trade | Volume 302,390 | 52 Wk Hi 1.78 | 52 Wk Low 0.76 |
| Market Cap 26.7 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 28,694,275.00 | EPS (TTM) -0.47 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 7 |
| Number of Buys | 0 | 7 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 114400 |
| Last 10 Buys | Shares |
|---|---|
| Graham G. Miao | 1,000 |
| Graham G. Miao | 1,000 |
| Nancy Lurker | 1,000 |
| Gerald R. Melillo | 1,000 |
| Nancy Lurker | 1,000 |
| Jeffrey E. Smith | 1,000 |
| Jeffrey E. Smith | 1,000 |
| Nancy Lurker | 1,000 |
| Nancy Lurker | 1,000 |
| Nancy Lurker | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Gerald R. Melillo | 1,000 |
| Gerald R. Melillo | 1,000 |
| Gerald R. Melillo | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 4.5 | 4.5 | 4.5 | 4.5 |
| Low Target Price Estimate | 3 | 3 | 3 | 3 |
| Mean Target Price Estimate | 3.5 | 3.5 | 3.5 | 3.5 |
| Standard Deviation | 0.87 | 0.87 | 0.87 | 0.87 |
| Date of Most Recent Estimate | 05/16/18 | 05/16/18 | 05/16/18 | 05/16/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-06-14 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 60 | 2018-05-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 13 | 2018-05-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-05-07 |
| S-8 | Securities offered to employees under employee benefit plans | 12 | 2018-04-30 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 31 | 2018-04-30 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-04-11 |
| 10-K | Annual report with a comprehensive overview of the company | 132 | 2018-03-23 |
| 8-K | Report of unscheduled material events or corporate changes. | 14 | 2018-03-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-03-13 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
